Payment overview · 2025
General Payments
$499.76
24 reported records · 20 companies
Healthcare provider profile · identity verified
Kellie L Binegar, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · WASHINGTON COURT HOUSE, OH · NPI 1356724751
Verified facts
What the public records show
CMS Open Payments records show Kellie L Binegar, APRN received $499.76 in general payments during 2025 across 24 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 13.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.99 | 13.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $54.92 | 11.0% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.53 | 8.3% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $32.09 | 6.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.17 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $23.44 | 4.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.42 | 4.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.33 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $21.28 | 4.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.21 | 4.2% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.18 | 4.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.58 | 4.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $17.53 | 3.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $17.18 | 3.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $16.51 | 3.3% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $16.12 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.65 | 3.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.57 | 3.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.87 | 2.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $12.19 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $499.76 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.99 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $54.92 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $41.53 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $32.09 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.17 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $21.28 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.21 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $16.51 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.57 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $12.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 229 | 68 |
| Gabapentin | Gabapentin | 187 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 181 | 42 |
| Omeprazole | Omeprazole | 167 | 48 |
| Amlodipine Besylate | Amlodipine Besylate | 166 | 49 |
| Lisinopril | Lisinopril | 138 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 108 | 31 |
| Losartan Potassium | Losartan Potassium | 101 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 98 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 25 |
| Sertraline Hcl | Sertraline Hcl | 92 | 29 |
| Metformin Hcl | Metformin Hcl | 87 | 27 |
| Furosemide | Furosemide | 86 | 31 |
| Simvastatin | Simvastatin | 84 | 20 |
| Prednisone | Prednisone | 76 | 62 |
| Trazodone Hcl | Trazodone Hcl | 71 | 21 |
| Metformin Hcl Er | Metformin Hcl | 69 | 21 |
| Montelukast Sodium | Montelukast Sodium | 61 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | 18 |
| Azithromycin | Azithromycin | 51 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 13 |
| Lorazepam | Lorazepam | 49 | 14 |
| Alendronate Sodium | Alendronate Sodium | 48 | 16 |
| Tramadol Hcl | Tramadol Hcl | 47 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Ozempic | Semaglutide | 46 | 12 |
| Potassium Chloride | Potassium Chloride | 46 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 45 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | 16 |
| Meloxicam | Meloxicam | 43 | 18 |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Carvedilol | Carvedilol | 40 | 13 |
| Famotidine | Famotidine | 38 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 37 | 17 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | 12 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | 12 |
| Eliquis | Apixaban | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 22 |
| Pregabalin | Pregabalin | 26 | suppressed |
| Allopurinol | Allopurinol | 25 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 22 | 16 |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $499.76 · 24 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, Doc Band, FREESTYLE LIBRE 3, JATENZO, NEXPLANON, NURTEC ODT, Ohtuvayre, QULIPTA, Qelbree, REXULTI, TRINTELLIX, UBRELVY, Veozah, Wegovy, XIFAXAN, YUPELRI, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error